|
|
News Breaks | | | | October 3, 2012 | | 08:49 EDT |  | ACAD | ACADIA pimavanserin chances of success have improved, says Roth Capital
Roth Capital believes that a recent article in the journal Schizophrenia Research could increase use of ACADIA's pimavanserin as an off-label schizophrenia treatment. The firm thinks that changes made to the current study of the drug compared with previous studies should cause it to yield statistically significant results, and Roth maintains a $3 target and Buy rating on the shares. | |
|
News For ACAD From The Last 14 Days Check below for free stories on ACAD the last two weeks. |
|
|
| May 15, 2013 | | 08:01 EDT |  | ACAD | ACADIA 8M share Spot Secondary priced at $12.50
 Subscribe for More Information | | | May 14, 2013 | | 16:01 EDT | | ACAD | ACADIA files to sell common stock, no amount given
Subscribe for More Information | | | May 7, 2013 | | 16:04 EDT |  | ACAD | ACADIA expects to use $28M-$32M in cash to fund FY13 operations
Subscribe for More Information | | | 16:03 EDT |  | ACAD | ACADIA reports Q1 EPS (8c), consensus (8c)
Reports Q1 revenue $417,000, consensus $450,000. | |
|
|
|
|
|
|
